Navigation Links
Global Markets for Marine-Derived Pharmaceuticals
Date:11/21/2011

NEW YORK, Nov. 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets for Marine-Derived Pharmaceuticals

http://www.reportlinker.com/p0687764/Global-Markets-for-Marine-Derived-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

"The search for bioactive metabolites from marine microbes has only just begun"—David Newman, D. Phil, and Russell Hill, PhD, New Drugs from Marine Microbes: The Tide is Turning (2006)

STUDY GOALS AND OBJECTIVES

BCC's goal in conducting this study was to determine the current status of the global marine-derived pharmaceutical market, including its growth potential during the period of 2011 to 2016. Our key objective is to present a comprehensive analysis of marine life and technology as they relate to pharmaceutical applications and to forecast this market's future direction.

REASONS FOR DOING THIS STUDY

Our understanding of marine life only began during the last half of the 20th century. The first marine discovery that led to a pharmaceutical drug began in the 1950s when chemists Bergmann and Feeney isolated nucleosidic compounds from the Caribbean sponge Cryptotethya crypta. Marine drugs on the market today can be traced to this discovery (e.g., anticancer drug cytarabine).

While marine life is used for many applications, including food and industrial processing, its use in the pharmaceutical industry has just begun. Marine life offers a complex and diverse genetic resource unavailable on land, which has led to the exploration of the oceans to find new tests and cures for illnesses. Entire classes of antibiotics desperately needed for a world surviving on relatively few antibiotics, which people are becoming resistant to, could be found in just a few marine samples.

This report describes the potential of marine research and its growth prospects. It is estimated that marine-derived drugs will essentially double in number from 2011 to 2016. Because marine-derived drugs already account for a few powerful drugs, this area of the drug industry has already generated billions of dollars to date.

SCOPE OF REPORT

The scope of this study encompasses research organizations, the U.S. government chiefly in the form of the National Cancer Institute (NCI), and companies that develop or help in the development process of pharmaceuticals derived from marine life. Included are extensive descriptions, perspectives, and predictive information, including forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.

INTENDED AUDIENCE

In this report, marine-derived pharmaceuticals are described in terms of their history in medicine, technology types and categories, research organizations, major companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This study will be of interest to non-profits and the government sector as well as the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies as well as all those interested in or actively working in drug and imaging agent research and investors in all of the above.

METHODOLOGY

BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing the financial value of marine-derived pharmaceuticals. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company and government officials as well as experts in academia.

INFORMATION SOURCES

BCC's analysis includes the review of more than 50 companies and information from financial and trade publications as well as the U.S. Food and Drug Administration (FDA). Included were pharmaceutical and biotechnology companies as well as support companies to them.

CHAPTER ONE: INTRODUCTION 1

STUDY GOALS AND OBJECTIVES . 1

REASONS FOR DOING THIS STUDY . 1

SCOPE OF REPORT .. 2

INTENDED AUDIENCE 2

METHODOLOGY ... 2

INFORMATION SOURCES ... 2

ABOUT THE AUTHOR .. 3

RELATED BCC REPORTS 3

BCC ONLINE SERVICES .. 4

DISCLAIMER . 4

CHAPTER TWO: EXECUTIVE SUMMARY ... 5

SUMMARY TABLE GLOBAL FORECAST FOR MARINE-DERIVED

DRUGS BY TYPE, THROUGH 2016 ($ MILLIONS) ... 5

SUMMARY FIGURE GLOBAL FORECAST FOR MARINE-DERIVED

DRUGS, 2010-2016 ($ MILLIONS) 6

EXECUTIVE SUMMARY (CONTINUED) 7

INVESTMENT AND PATH FORWARD ... 8

INVESTMENT AND PATH FORWARD (CONTINUED) .. 9

KEY DRIVERS .. 10

KEY CHALLENGES. 11

KEY TRENDS ... 11

DEVELOPMENT OF MICROBES SYMBIOTIC WITH MARINE

INVERTEBRATES ... 12

USE OF ALGAE IN NOVEL WAYS . 12

GREATER USE OF ESTABLISHED MARINE LIFE

LIBRARIES ... 13

CONTINUED FOCUS ON CANCER 13

EXPANSION OF KNOWLEDGE AND USE OF

CONOPEPTIDES . 14

IMMUNE CELL INDUCEMENT THERAPY ... 14

INVESTMENT LANDSCAPE .. 14

KEY INVESTMENTS/COLLABORATIONS IN MARINEDERIVED

DRUG DEVELOPMENT 15

Abbott Laboratories and Seattle Genetics .. 15

Algenics, IFREMER, Roquette Group 15

Aphios Corp., Novartis, Bayer, Bristol-Myers Squibb, Eli

Lilly, Baxter Healthcare, Sigma-Aldrich .. 15

Aquapharm Biodiscovery, Ltd. and Albany Molecular

Research Group .. 16

ArcticZymes, Universities in Tromsø, Trondheim

(NTNU/Norway), and Umea (Sweden) .. 16

ASKA and Yakult Honsha .. 16

AstraZeneca (MedImmune) and Xenome ... 16

Azur Pharma and Eisai ... 17

Boehringer Ingelheim, Sigma-Tau, Pacira . 17

Cognetix, Inc. and the University of Utah . 17

Genzyme and Abbott Laboratories . 17

Gilead Sciences, Inc. and UC Santa Cruz .. 17

GlaxoSmithKline and Pfizer ... 18

GlaxoSmithKline/Pronova, Affiris, and Stellar

Biotechnologies ... 18

GlycoMar and Verona Pharma ... 18

Johnson & Johnson, PharmaMar, and Taiho

Pharmaceuticals . 18

National Cancer Institute and Bristol-Myers Squibb 19

Nautilus Biosciences Canada, Inc. and the NRC-INH on

the campus of UPEI ... 19

Scripps Institution of Oceanography, Trius Therapeutics,

and Nereus Pharmaceuticals . 19

Seattle Genetics, Astellas, CellDex, Millennium ... 20

Stellar Biotechnologies, Bayer Innovation, Amgen, Merck,

Biovest, Neovacs, Affiris, GlaxoSmithKline .. 21

Triton Biopharma, University of Mississippi, PharmaMar ... 21

CHAPTER THREE: OVERVIEW .. 22

HISTORY OF MARINE DRUGS.. 22

HISTORY OF MARINE DRUGS (CONTINUED) 23

HISTORY OF MARINE DRUGS (CONTINUED) 24

TABLE 1 KEY DATES IN MARINE-DERIVED DRUG HISTORY 25

TABLE 2 GROWTH IN THE INTEREST IN MARINE NATURAL

PRODUCTS BASED ON THE NUMBER OF PRODUCTS

DESCRIBED IN SCIENTIFIC JOURNALS, 1999–2004 ... 26

MAJOR CATEGORIES OF MARINE DRUGS 26

MAIN CHEMICAL CLASSES ... 27

Phenols . 27

Steroids 27

Ether 27

Strigolactones .. 27

Peptides 28

MAIN MARINE LIFE GROUPINGS 28

Marine Microorganisms .. 29

Marine Algae 30

Marine Invertebrates .. 31

Porifera .. 31

Discodermolide .. 31

Cnidarians . 32

Ctenophora 32

Bryozoa .. 32

Mollusca 32

Echinoderms .. 33

Protozoa . 34

Chordates .. 34

FIGURE 1 THE TUNICATE ECTEINASCIDIA TURBINATE FROM

WHICH YONDELIS (TRABECTEDIN) FOR CANCER TREATMENT

IS MADE 34

FIGURE 2 MARINE SPECIES PER PHYLUM BASED ON WORMS ... 35

FIGURE 3 APPROXIMATION OF KNOWN VERSUS POSSIBLE

SPECIES WITHIN THREE PHYLA, 2011 ... 36

CHAPTER FOUR: MARKET LANDSCAPE . 37

COMMERCIALIZED MARINE LIFE DRUGS BY TYPE ... 37

ANTIVIRALS . 37

ANTI-LEUKEMIC DRUG . 37

IMMUNOTHERAPEUTIC 37

PAIN MEDICATION FOR CANCER PATIENTS 38

TRIGLYCERIDE-LOWERING DRUG .. 38

ANTICANCER DRUG ... 38

BREAST CANCER DRUG . 39

ANTIBODY DRUG CONJUGATE 39

FIGURE 4 COMMERCIALIZED MARINE DRUGS BY MARINE LIFE

TYPE, 2011 AND 2016 (NO. OF UNITS) 40

FIGURE 5 COMMERCIALIZED MARINE DRUGS*, 2010–2016

(NUMBER OF UNITS**) .. 41

FIGURE 6 GLOBAL FORECAST FOR MARINE-DERIVED DRUGS* BY

THERAPEUTIC CATEGORY, 2009-2016 ($ MILLIONS) ... 42

FIGURE 7 COMMERCIALIZED MARINE DRUGS BY THERAPEUTIC

AREA, 2011 (NUMBER OF UNITS EXPRESSED AS A %) ... 43

FIGURE 8 COMMERCIALIZED MARINE DRUGS BY MARINE LIFE

TYPE, 2016 (NUMBER OF UNITS EXPRESSED AS A %) 44

PHARMACEUTICAL MARKET IN GENERAL . 44

PHARMACEUTICAL MARKET IN GENERAL (CONTINUED) 45

FIGURE 9 GLOBAL PHARMACEUTICAL DRUG SALES, 2010 ($

BILLIONS) . 46

FIGURE 10 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL

SALES, 2010 AND 2016 (% OF MARKET SHARE) .. 47

TABLE 3 TOP 10 PHARMA IN SALES IN 2010 ($ BILLIONS) . 48

MARINE-DERIVED DRUG LANDSCAPE . 49

APPROVED DRUGS .. 50

AZT, Retrovir, Combivir, AZT/3TC (Zidovudine) ... 50

Zovirax (Acyclovir, Aciclovir) .. 51

Ara-C, Cytosar-U, or DepoCyt (Cytarabine)... 51

Vira-A (Vidarabine) . 52

Prialt (Ziconotide) 52

Lovaza/Omacor (Fish-Derived Omega-3s) .. 53

Immucothel/(Keyhole Limpet Hemocyanin) ... 53

Halaven (Eribulin Mesylate) ... 54

Yondelis (Trabectedin) 55

Adcetris (Brentuximab Vedotin) . 56

Adcetris (Brentuximab Vedotin) (Continued) . 57

TABLE 4 PHARMAMAR R&D PIPELINE IN THE U.S. OR EUROPE,

2011 58

DRUGS IN DEVELOPMENT 58

Phase III ... 58

Yondelis (Trabectedin) .. 58

BiovaxID 58

Phase II 59

Soblidotin (YHI-501) . 59

Aplidin (Plitidepsin) .. 59

TABLE 5 MARINE-DERIVED DRUGS APPROVED AND IN LATESTAGE

DEVELOPMENT*, 2011 .. 60

TABLE 5 (CONTINUED) 61

TABLE 5 (CONTINUED) 62

Affitope AD02 63

DMXBA . 63

Bryostatin .. 63

Plinabulin (NPI-2358) ... 64

Elisidepsin (Irvalec, PM02734) 64

PM1004 (Zalypsis) 65

Squalamine (Evison) . 65

CDX-011 65

Xen2174 . 66

Phase I.. 66

Affitope AD 03 ... 66

ASG-5ME .. 67

ASG-22ME. 67

Tasidotin (ILX-651) ... 67

Hemiasterlin (E7974) ... 68

Salinosporamide A (NPI-0052) . 68

SGN-75 .. 69

COMMERCIALIZATION LANDSCAPE BY 2016 .. 69

FORERUNNERS IN THE MARINE-DERIVED DRUG

COMMERCIALIZATION RACE .. 69

Aplidin (Plitidepsin): PharmaMar .. 69

PM01183 and Yondelis (Trabectedin): PharmaMar and

Johnson & Johnson 69

Plinabulin (NPI-2358): Nereus Pharmaceuticals ... 70

CDX-011: CellDex Therapeutics . 70

Envizon (Squalamine): Ohr Pharmaceuticals 70

BiovaxID: Biovest Using Stellar Biotechnologies' KLH. 71

BiovaxID: Biovest Using Stellar … (Continued) . 72

MECHANISMS OF ACTION ... 72

TABLE 6 MARINE-DERIVED DRUGS/DRUG CANDIDATE'S

MECHANISM OF ACTION . 73

MARINE DRUG CULTIVATION 73

MARINE DRUG CULTIVATION (CONTINUED) ... 74

MARINE DRUG CULTIVATION (CONTINUED) ... 75

TABLE 7 KEY MARINE-DERIVED PRODUCT LIBRARIES. 76

TABLE 7 (CONTINUED) ... 77

FIGURE 11 MARINE SAMPLE/MOLECULE CULTIVATION AND

PROCESSING 78

PRIVATE RESOURCES 79

Aphios Corp. . 79

Magellan Bioscience Group . 79

Phycosource.. 79

Aquapharm Biodiscovery, Ltd. 80

CASE STUDIES . 80

Movement of Drug from Lab to Trials 80

Academic-Industrial Collaboration . 81

PharmaMar Serves as an Example of an Integrated

Developer 82

CHALLENGES TO CULTIVATION/PRODUCTION ... 83

REGULATORY ENVIRONMENT ... 83

PATENTS .. 84

CASE STUDIES . 85

Development is Lagging behind Novel Patents . 85

Patenting Areas of Growth .. 86

MARINE DRUG DEVELOPMENT: AREAS OF FOCUS TO WATCH .. 86

ENZYMES .. 86

Enzymes (Continued) .. 87

Enzymes (Continued) .. 88

EXTREMOPHILES 89

Extremophiles (Continued) . 90

FLUORESCENT PROTEINS 91

Developments in Fluorescent Proteins ... 92

Photo-Activatable Green Fluorescent Protein (PAGFP)

. 92

Dronpa Fluorescent Protein Chromophore

Photoswitching 92

Photoconvertable Fluorescent Proteins ... 92

Fluorescent Proteins as Vectors ... 93

ANTICANCER/ONCOLOGY . 93

MMP Inhibitors ... 94

Protein Kinase C .. 94

Topoisomerase Inhibitors 94

Nuclear Factor-?B (NF-?B) Inhibitors ... 94

Hypoxia-Inducible Factors Inhibitors . 95

MARINE DRUG DEVELOPMENT RESEARCH 95

TABLE 8 KEY MARINE-DERIVED DRUG RESEARCH CANDIDATES:

COMPOUNDS BY DRUG TYPE ... 95

TABLE 8 (CONTINUED) 96

TABLE 8 (CONTINUED) ... 97

TABLE 8 (CONTINUED) 98

DISEASES/CONDITIONS MOST OFTEN TREATED WITH MARINE

DRUGS . 99

CANCER DRUG PIPELINE: 2011 AND BEYOND . 99

Breast Cancer .. 99

TABLE 9 GLOBAL PHASE III PIPELINE FOR BREAST CANCER

THROUGH 2016 .. 100

Brain Cancer .. 100

TABLE 10 GLOBAL PHASE III PIPELINE FOR BRAIN OR CNS

CANCER, THROUGH 2016 ... 101

Bladder Cancer .. 101

TABLE 11 GLOBAL PHASE III PIPELINE FOR BLADDER CANCER,

THROUGH 2016 .. 101

Colorectal Cancer... 102

TABLE 12 GLOBAL PHASE III PIPELINE FOR COLORECTAL

CANCER, THROUGH 2016 ... 102

Head and Neck Cancer .. 102

TABLE 13 GLOBAL PHASE III PIPELINE FOR HEAD AND NECK

CANCER, THROUGH 2016 ... 103

Kidney Cancer ... 103

TABLE 14 GLOBAL PHASE III PIPELINE FOR KIDNEY CANCER,

THROUGH 2016 .. 104

Leukemia ... 104

TABLE 15 GLOBAL PHASE III PIPELINE FOR LEUKEMIA,

THROUGH 2016 .. 105

TABLE 15 (CONTINUED) 106

Liver Cancer .. 106

TABLE 16 GLOBAL PHASE III PIPELINE FOR LIVER CANCER

THROUGH 2016 .. 106

TABLE 16 (CONTINUED) 107

Lung Cancer ... 107

TABLE 17 GLOBAL PHASE III PIPELINE FOR LUNG CANCER

THROUGH 2016 .. 107

TABLE 17 (CONTINUED) 108

Lymphoma . 108

TABLE 18 GLOBAL PHASE III PIPELINE FOR LYMPHOMA,

THROUGH 2016 .. 109

TABLE 18 (CONTINUED) 110

Multiple Myeloma .. 110

TABLE 19 GLOBAL PHASE III PIPELINE FOR MULTIPLE

MYELOMA, THROUGH 2016 110

Ovarian Cancer .. 111

TABLE 20 GLOBAL PHASE III PIPELINE FOR OVARIAN CANCER,

THROUGH 2016 .. 111

Pancreatic Cancer .. 111

TABLE 21 GLOBAL PHASE III PIPELINE FOR PANCREATIC

CANCER, THROUGH 2016 ... 112

Prostate Cancer . 112

TABLE 22 GLOBAL PHASE III PIPELINE FOR PROSTATE CANCER,

THROUGH 2016 .. 113

TABLE 22 (CONTINUED) 114

Sarcoma .. 114

TABLE 23 GLOBAL PHASE III PIPELINE FOR SARCOMA, THROUGH

2016 .. 114

Skin Cancer 115

TABLE 24 GLOBAL PHASE III PIPELINE FOR SKIN CANCER,

THROUGH 2016 .. 115

Solid Tumors .. 116

TABLE 25 GLOBAL PHASE III PIPELINE FOR SOLID TUMORS,

THROUGH 2016 .. 116

Stomach Cancer . 116

TABLE 26 GLOBAL PHASE III PIPELINE FOR STOMACH CANCER,

THROUGH 2016 .. 116

CHAPTER FIVE: COMPANY PROFILES .. 117

ABBOTT LABORATORIES 117

AFFIRIS AG 117

AKER BIOMARINE ASA ... 118

ALGENICS .. 119

APHIOS CORP. ... 120

APP PHARMACEUTICALS ... 121

ARCTICZYMES .. 122

ASKA PHARMACEUTICAL CO., LTD. 123

ASTELLAS (AGENSYS, INC.) ... 124

ASTELLAS (AGENSYS, INC.) (CONTINUED) . 125

AQUAPHARM BIODISCOVERY, LTD. 126

AZUR PHARMA .. 126

BASF SE .. 127

BAYER INNOVATION ... 128

BEDFORD LABORATORIES 129

BIOSYN CORP. ... 130

BIOVEST INTERNATIONAL, INC. .. 130

BTG INTERNATIONAL, LTD. .. 131

CATABASIS PHARMACEUTICALS, INC. ... 132

CELLDEX THERAPEUTICS . 132

CENTOCOR ORTHO BIOTECH ... 133

COGNETIX, INC. ... 133

COMENTIS . 134

CYANOTECH CORP. . 134

EISAI CO., LTD. . 135

ELAN CORP. (ELAN PHARMACEUTICALS, INC.) 136

EUROPHARMA, INC. 136

GENZYME .. 137

GILEAD SCIENCES, INC. . 138

GLAXOSMITHKLINE 138

GLYCOMAR, LTD. . 139

TABLE 27 GLYCOMAR POLYSACCHARIDE CHARACTERIZATION

SERVICES ... 140

TABLE 27 (CONTINUED) 141

GILEAD SCIENCES ... 141

HOSPIRA, INC. .. 142

IMMUNOPHOTONICS .. 142

INTEGRIN ADVANCED BIOSYSTEMS ... 143

INTERMED DISCOVERY GMBH . 143

INTRACEL .. 144

KLINIPHARM GMBH 144

KLINIPHARM GMBH (CONTINUED) .. 145

MAGELLAN BIOSCIENCE GROUP, INC 146

MARINE POLYMER TECHNOLOGIES, INC. . 147

MARINOVA PTY, LTD. .. 147

MARINOVA PTY, LTD. (CONTINUED) 148

MARTEK BIOSCIENCES CORP. .. 149

MEDIMETRIKS PHARMACEUTICALS ... 149

MERA PHARMACEUTICALS ... 150

MILLENNIUM, A TAKEDA ONCOLOGY CO. 151

NAUTILUS BIOSCIENCES CANADA, INC. 151

NÉOVACS ... 152

NEUROBIOPHARM, INC. (PART OF NEPTUNE TECHNOLOGIES) .. 153

NEREUS PHARMACEUTICALS .. 154

NEREUS PHARMACEUTICALS (CONTINUED) . 155

OHR PHARMACEUTICALS .. 156

PACIRA PHARMACEUTICALS, INC. .. 156

PHARMAMAR 157

PHARMAMAR (CONTINUED) ... 158

PHARMA MARINE USA, LLC .. 159

PHYCOSOURCE 160

PML APPLICATIONS, LTD. .. 160

PRIMEX EHF .. 161

PROLUME, LTD. 161

PRONOVA BIOPHARMA ASA .. 162

SEA RUN HOLDINGS ... 163

SEATTLE GENETICS, INC. .. 164

SEATTLE GENETICS, INC. (CONTINUED) 165

SIGMA-TAU PHARMACEUTICALS, INC. ... 166

STELLAR BIOTECHNOLOGIES .. 166

STELLAR BIOTECHNOLOGIES (CONTINUED) . 167

STELLAR BIOTECHNOLOGIES (CONTINUED) . 168

STRATEGRO INTERNATIONAL, LLC 169

TAIHO PHARMACEUTICALS .. 169

TEQUESTA BIOVENTURES 170

TRITON BIOPHARMA ... 170

TRIUS THERAPEUTICS ... 171

VERONA PHARMA, PLC ... 172

XENOME, LTD. .. 172

YAKULT HONSHA CO, LTD. ... 173

ZELTIA GROUP (GRUPO ZELTIA) .. 173

ZELTIA GROUP (GRUPO ZELTIA) (CONTINUED) . 174

ZELTIA GROUP (GRUPO ZELTIA) (CONTINUED) . 175

APPENDIX: RESOURCES ... 176

TABLE 28 MARINE RESEARCH RESOURCES BY CATEGORY ... 176

TABLE 28 (CONTINUED) 177

TABLE 28 (CONTINUED) 178

TABLE 29 KEY RESEARCHERS/LEADERS AFFECTING MARINEDERIVED

DRUG INDUSTRY ... 178

TABLE 29 (CONTINUED) 179

To order this report:

: Global Markets for Marine-Derived Pharmaceuticals

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Perceptive Informatics® Global Survey Results Indicate Wide Use of Industry-Standard Medical Imaging Metrics to Meet Study Milestones
2. Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process
3. Ceramic Fiber Market by Type, Applications and Global Forecasts (2011-2016)
4. White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution
5. Global Orthopedics Devices Market (2011 - 2016)
6. Sustainability in the Global Pharmaceutical Industry 2011-2012: Market Trends and Opportunities, Profitability and Budget Forecasts, Pharmaceutical Industry Procurement and Marketing Initiatives
7. The Global Cardiovascular Monitoring & Diagnostic Devices Market is Booming: Expected to Attain a Market Size of USD 1.3 Billion by 2016
8. HeartSine® Technologies Launches New Global Website
9. Emerging Pharmaceutical Markets Globally
10. Astellas Signs United Nations Global Compact
11. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):